1
|
Luchetta A, Taliercio C, Cruz N, Martini G, Manduchi G, Rigoni A, Trevisan L, Paolucci F, Labate C, Breda M, Capobianco R, Moressa M, Molon F, Sartore A, Simionato P, Zampiva E, Barbato P, Carraro M, Migliorato L. As built design of the control systems of the ITER full-size beam source SPIDER in the neutral beam test facility - A critical review. FUSION ENGINEERING AND DESIGN 2023. [DOI: 10.1016/j.fusengdes.2023.113624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
2
|
Azzena U, Carraro M, Pisano L, Pintus E, Pintus S, Polese R, Satta P, Gaspa S, De Luca L, Taras A, Garroni S. Size Selectivity in the Hydroxylation of Esters of Unsaturated Fatty Acids. EUR J LIPID SCI TECH 2022. [DOI: 10.1002/ejlt.202100234] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
3
|
Bessi V, Giacomucci G, Mazzeo S, Bagnoli S, Padiglioni S, Balestrini J, Tomaiuolo G, Piaceri I, Carraro M, Bracco L, Sorbi S, Nacmias B. PER2 C111G polymorphism, cognitive reserve and cognition in subjective cognitive decline and mild cognitive impairment: a 10-year follow-up study. Eur J Neurol 2020; 28:56-65. [PMID: 32896064 DOI: 10.1111/ene.14518] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2020] [Accepted: 08/31/2020] [Indexed: 02/06/2023]
Abstract
BACKGROUND AND PURPOSE CLOCK and PER2 genes have been implicated in sleep-wake cycle alterations and neurodegenerative diseases. Our aim was to evaluate the effect of CLOCK T3111C and PER2 C111G on cognitive functioning in subjective cognitive decline (SCD) patients and mild cognitive impairment (MCI) patients at the baseline of a longitudinal study, and the effect of these two polymorphisms on the progression to Alzheimer's disease (AD) of the two groups. METHODS Sixty-eight subjects (41 SCD and 27 MCI) who underwent clinical evaluation, neuropsychological assessment, CLOCK and PER2 genotyping at baseline and neuropsychological follow-up every 2 years for a mean time of 10 years were included. Subjects who developed AD (SCD-c and MCI-c) and non-converters (SCD-nc, MCI-nc) were considered. RESULTS CLOCK T3111C was detected in 47% of cases (21 SCD, 11 MCI) and PER2 C111G in 19% of cases (eight SCD and five MCI). PER2 G carriers presented lower premorbid intelligence score (P = 0.049), fewer years of education (P = 0.007) and a lower frequency of family history of AD (P = 0.04) than G non-carriers. MCI PER2 G carriers had worse performance in tests assessing memory, executive function, language and visuospatial abilities at baseline. During follow-up, two SCD and 15 MCI subjects progressed to AD: both of the SCD-c subjects presented the PER2 G allele, while none of the SCD PER2 G non-carriers converted to AD (P = 0.003). CONCLUSION PER2 seems to have a role in cognitive reserve and cognition in SCD and MCI patients. Nevertheless, further studies are needed to assess the role of PER2 C111G on the risk of progression to AD.
Collapse
|
4
|
Steingo B, Al Malik Y, Bass AD, Berkovich R, Carraro M, Fernández Ó, Ionete C, Massacesi L, Meuth SG, Mitsikostas DD, Pardo G, Simm RF, Traboulsee A, Choudhry Z, Daizadeh N, Compston DAS. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol 2020; 267:3343-3353. [PMID: 32583052 PMCID: PMC7578137 DOI: 10.1007/s00415-020-09983-1] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2020] [Revised: 06/04/2020] [Accepted: 06/06/2020] [Indexed: 02/07/2023]
Abstract
BACKGROUND In the phase 2 CAMMS223 trial (NCT00050778), alemtuzumab significantly improved clinical and MRI outcomes versus subcutaneous interferon beta-1a over 3 years in treatment-naive patients with relapsing-remitting MS. Here, we assess efficacy and safety of alemtuzumab over 12 years in CAMMS223 patients who enrolled in the CAMMS03409 extension (NCT00930553), with available follow-up through the subsequent TOPAZ extension (NCT02255656). METHODS In CAMMS223, patients received 2 alemtuzumab courses (12 mg/day; baseline: 5 days; 12 months later: 3 days); 22% received a third course. In the open-label, nonrandomized extensions, patients could receive as-needed additional alemtuzumab or other disease-modifying therapies. RESULTS Of 108 alemtuzumab-treated patients in CAMMS223, 60 entered the CAMMS03409 extension; 33% received a total of 2 alemtuzumab courses, and 73% received no more than 3 courses through Year 12. Over 12 years, annualized relapse rate was 0.09, 71% of patients had stable or improved Expanded Disability Status Scale scores, and 69% were free of 6-month confirmed disability worsening. In Year 12, 73% of patients were free of MRI disease activity. Cumulatively throughout the extensions (Years 7-12), 34% of patients had no evidence of disease activity. Adverse event (AE) incidence declined through Year 12. Infusion-associated reactions peaked at first course and declined thereafter. Cumulative thyroid AE incidence was 50%; one immune thrombocytopenia event occurred, and there were no autoimmune nephropathy cases. CONCLUSIONS Alemtuzumab efficacy was maintained over 12 years in CAMMS223 patients, with 73% receiving no more than three courses. The safety profile in this cohort was consistent with other alemtuzumab clinical trials.
Collapse
|
5
|
Mazzeo S, Padiglioni S, Bagnoli S, Carraro M, Piaceri I, Bracco L, Nacmias B, Sorbi S, Bessi V. Assessing the effectiveness of subjective cognitive decline plus criteria in predicting the progression to Alzheimer’s disease: an 11‐year follow‐up study. Eur J Neurol 2020; 27:894-899. [DOI: 10.1111/ene.14167] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2019] [Accepted: 02/06/2020] [Indexed: 12/18/2022]
|
6
|
Crosetti E, Bertolin A, Molteni G, Bertotto I, Balmativola D, Carraro M, Sprio AE, Berta GN, Presutti L, Rizzotto G, Succo G. Patterns of recurrence after open partial horizontal laryngectomy types II and III: univariate and logistic regression analysis of risk factors. ACTA ACUST UNITED AC 2020; 39:235-243. [PMID: 31501615 PMCID: PMC6734199 DOI: 10.14639/0392-100x-2409] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Accepted: 01/11/2019] [Indexed: 11/23/2022]
Abstract
In choosing the best surgical treatment (total or partial laryngectomy) for patients affected by laryngeal squamous cell carcinoma (SCC), it is still necessary to identify a link between prognostic factors and oncological outcomes. A retrospective analysis of clinical outcomes of 819 patients affected by laryngeal cancer who underwent OPHL type II and III between 1995 to 2014 was carried out. Focusing on recurrence and its site (local, regional or distant), our cohort has been divided in two groups: patients showing recurrence (n = 108) vs those without recurrence (n = 711). Thirteen clinical-pathological parameters have been studied by univariate and multivariate analysis to identify possible correlations between recurrence and oncological outcomes (overall survival (OS), disease free survival (DFS), disease specific survival (DSS), laryngectomy free survival (LSF), laryngectomy free freedom (FFL). In multivariate analysis, we found 4 negative prognostic factors for recurrence: site of tumour (> supraglottic), cartilage invasion (> if present), perineural invasion (> if present) and type of OPHL (> in OPHL type III). The knowledge and detection of negative prognostic factors for the risk of recurrence (pN classification, cartilage involvement, perineural invasion, and thus the type of surgical treatment adopted) could increase the already well-established potentiality of OPHLs in treating cases with a safe indication after careful discussion in the tumour board.
Collapse
|
7
|
Wiendl H, Carraro M, Comi G, Izquierdo G, Kim HJ, Sharrack B, Tornatore C, Daizadeh N, Chung L, Jacobs AK, Hogan RJ, Wychowski LV, Van Wijmeersch B. Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION 2019; 7:7/1/e635. [PMID: 31662412 PMCID: PMC6865853 DOI: 10.1212/nxi.0000000000000635] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Accepted: 09/05/2019] [Indexed: 11/15/2022]
Abstract
OBJECTIVE To examine the association between peripheral blood lymphocyte pharmacodynamics and autoimmune adverse events (AEs) or return of disease activity in alemtuzumab-treated patients with relapsing-remitting MS. METHODS Patients received 2 alemtuzumab courses (12 mg/d IV; 5 days at baseline, 3 days 12 months later) in the 2-year Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis studies (NCT00530348 and NCT00548405) and could then receive as-needed alemtuzumab or other disease-modifying therapy in a 4-year extension (NCT00930553). Lymphocytes were phenotyped quarterly over 2 years using fluorescence-activated cell sorting. Pharmacodynamic assessments included counts of total lymphocytes, CD3+ T cells, CD4+/CD8+ T cells (total/naive/memory/regulatory [Treg]), and CD19+ B cells (total/immature/mature/memory) and ratios of CD19+ (total/immature/mature/memory) to Treg (CD4+/CD8+) counts. Assessed autoimmune AEs included immune thrombocytopenia, nephropathies, and thyroid events. Efficacy assessments included relapses, 6-month confirmed disability worsening (CDW), and MRI disease activity. RESULTS Lymphocyte repopulation patterns, including ratios between distinct lymphocyte subsets (e.g., CD19+ to Treg cell count ratios), showed no significant differences over 2 years in patients developing/not developing autoimmune AEs, relapses, CDW, or MRI activity through 6 years following alemtuzumab. Lymphocyte kinetics were also unrelated to multiple autoimmune AEs or extreme clinical phenotypes. CONCLUSIONS Repopulation kinetics of the evaluated peripheral lymphocyte subsets did not predict autoimmune AE occurrence or disease activity, including return of disease activity after 2 alemtuzumab courses. Further study is needed to investigate potential antigen-level markers of treatment response.
Collapse
|
8
|
Zanon F, Marcantoni L, Pastore G, Baracca E, Picariello C, Lanza D, Maddalozzo A, Giatti S, Carraro M, Roncon L, Barbetta A, Di Gregorio F. P6547The energy cost of His bundle pacing can be curtailed. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.1137] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
His bundle pacing (HBP) allows physiological ventricular activation and prevents the electrical and mechanical desynchronization generally induced by myocardial stimulation, which can increase the risk of atrial fibrillation and heart failure. On the other hand, reliable HBP capture often requires higher energy than conventional myocardial pacing. This reduces the expected life of the stimulator and might limit the diffusion of HBP in the clinical practice.
Purpose
Decreasing HBP current drain by careful management of stimulation safety margin and pulse duration.
Methods
In 28 patients undergoing DDD pacing with HBP, a third lead was implanted in RV apex to provide back-up pacing on demand. HBP and apical leads were connected, respectively, to the V1 and V2 channels of a 3-chamber stimulator. When HBP was effective, apical sensing occurred within the VV delay and prevented V2 stimulation. In contrast, in case of HBP failure, V2 sensing was missing and apical back-up pacing was promptly delivered at the end of the VV delay. The availability of a back-up pulse on demand allowed reducing the HBP safety margin with no risk. Furthermore, the individual HBP strength-duration curve was derived in the aim of optimizing the Hisian pulse parameters, which are the major determinants of the device current drain.
Results
Correct back-up inhibition by successful HBP and stimulation in the event of capture loss was achieved in all the patients. The latency from Hisian pacing to apical sensing averaged 96±14 ms. According to the pacemaker counters, no back-up pulse was delivered in daily life in 59% of patients. In the remaining, the prevalence of back-up stimulation never exceeded 15% of paced ventricular cycles. The high HBP threshold was essentially due to an increased rheobase (1.2±0.6 V), while the chronaxie ranged from 0.30 to 0.53 ms in 71% of patients (median 0.44 ms), exceeding 0.6 ms only in 29% of the cases. An average current saving of 5.4±3.0 μA was obtained at the expense of a mild reduction in HBP safety margin (from 1.6±0.2 to 1.4±0.1 times).
HBP and apical back-up
Conclusions
Back-up stimulation on demand is a reliable option to decrease HBP current drain and prolong the stimulator service life with full safety. In most of the cases, significant saving can be achieved by pulse shortening, as the chronaxie time is in the same range as with myocardial stimulation and longer pulses are not required. A pulse duration exceeding 0.6 ms is indicated in less than 1/3 of the implants.
Collapse
|
9
|
Kidd J, Carraro M, Essick K, Johnson E, Reichard J. Impact of specialty pharmacy taking ownership of the prior authorization process of multiple sclerosis specialty medications to increase access todisease-modifying therapy. J Drug Assess 2018. [DOI: 10.1080/21556660.2018.1521069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
10
|
Zanon F, Marcantoni L, Pastore G, Baracca E, Carraro M, Picariello C, Giatti S, Lanza D, Aggio S, D'Elia K, Roncon L. 5310His bundle pacing in patients with low ejection fraction at implant: long-term follow-up. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.5310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Zanon F, Marcantoni L, Pastore G, Baracca E, Picariello C, Galasso MP, Lanza D, Giatti S, Aggio S, D'Elia K, Carraro M, Roncon L. P5739LV lead apical position could be the best option in selected CRT patients. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Zanon F, Marcantoni L, Pastore G, Baracca E, Picariello C, Lanza D, Giatti S, D'Elia K, Conte L, Carraro M, Roncon L. P5736MPP reduces the ventricular arrhythmias burden compared to standard biventricular pacing in CRT patients. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Zanon F, Marcantoni L, Baracca E, Pastore G, Giatti S, Aggio S, Picariello C, Lanza D, Roncon L, Noventa F, Conte L, Carraro M, Rinuncini M, Galasso MP, D'elia K. P1132LV lead apical placement could be the best option in selected patients candidate to CRT. Europace 2018. [DOI: 10.1093/europace/euy015.618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Zanon F, Marcantoni L, Pastore G, Giatti S, Baracca E, Aggio S, Picariello C, Roncon L, Conte L, Lanza D, D' Elia K, Carraro M, Galasso MP, Rinuncini M. P411His pacing improved ejection fraction on long term follow-up in the subgroup of patients with low ejection fraction at implant. Europace 2018. [DOI: 10.1093/europace/euy015.222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Zanon F, Marcantoni L, Pastore G, Baracca E, Aggio S, Carraro M, Picariello C, Lanza D, Giatti S, Rinuncini M, Galasso MP, D'elia K, Roncon L, Conte L. 42His bundle pacing in BBB patients: outcomes over a long-term follow-up. Europace 2018. [DOI: 10.1093/europace/euy015.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Zanon F, Marcantoni L, Pastore G, Baracca E, Picariello C, Lanza D, Giatti S, Aggio S, Carraro M, Conte L, D'elia K, Roncon L, Rinuncini M, Galasso MP. 43Hisian pacing with apical back-up on demand is safe and effective. Europace 2018. [DOI: 10.1093/europace/euy015.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Zanon F, Marcantoni L, Baracca E, Pastore G, Giatti S, Aggio S, Picariello C, Lanza D, Roncon L, D'elia K, Noventa F, Carraro M, Rinuncini M, Galasso MP, Conte L. P1143MPP reduces the ventricular arrhythmias burden compared to standard biventricular pacing in CRT patients. Europace 2018. [DOI: 10.1093/europace/euy015.629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Zizzari A, Bianco M, del Mercato L, Carraro M, Bonchio M, Frigione M, Montagna F, Gigli G, Viola I, Arima V. Self-powered catalytic microfluidic platforms for fluid delivery. Colloids Surf A Physicochem Eng Asp 2017. [DOI: 10.1016/j.colsurfa.2017.05.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
19
|
Zanon F, Marcantoni L, Pastore G, Baracca E, Giau G, Picariello C, Aggio S, Carraro M, Roncon L, Lanza D. P1351Long-term follow-up of His pacing in a single center experience. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1351] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Zanon F, Marcantoni L, Pastore G, Picariello C, Aggio S, Lanza D, Roncon L, Carraro M, Conte L, Rinuncini M, D'elia K, Galasso MP, Baracca E. 177Direct his-bundle pacing in cardiac resynchronization therapy. Europace 2017. [DOI: 10.1093/ehjci/eux136.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Pastore G, Marcantoni L, Zanon F, Maines M, Corbucci G, Noventa F, Piccariello C, Baracca E, Carraro M, Conte L, Roncon L. P1006Patients with RBBB and concomitant delayed LV activation respond to CRT. Europace 2017. [DOI: 10.1093/ehjci/eux151.187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Zanon F, Marcantoni L, Pastore G, Baracca E, Lanza D, Picariello C, Aggio S, Roncon L, Conte L, Carraro M, Noventa F, Prinzen F. P990Patients with LBBB have a longer LV electrical delay and a better acute hemodynamic improvement during CRT compared to non-LBBB patients. Europace 2017. [DOI: 10.1093/ehjci/eux151.171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
23
|
Zanon F, Marcantoni L, Pastore G, Lanza D, Conte L, Picariello C, Aggio S, Roncon L, Galasso MP, Rinuncini M, D'elia K, Carraro M, Baracca E. P991Long term follow-up of the hisian pacing system: technical and clinical outcomes in a single centre experience. Europace 2017. [DOI: 10.1093/ehjci/eux151.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Seyed Dorraji M, Amani-Ghadim A, Hanifehpour Y, Woo Joo S, Figoli A, Carraro M, Tasselli F. Performance of chitosan based nanocomposite hollow fibers in the removal of selenium(IV) from water. Chem Eng Res Des 2017. [DOI: 10.1016/j.cherd.2016.10.043] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Azzena U, Carraro M, Pisano L, Mocci F, Antonello S, Maran F. Reducing properties of 1,2-dipyridyl-1,2-disodioethanes: chemical validation of theoretical and electrochemical predictions. RSC Adv 2016. [DOI: 10.1039/c6ra03303b] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Theoretical calculations and electrochemical analysis were used to set up a relative scale for the reducing strength of the dianions of 1,2-dipyridylethenes, validated by studying their reactivity towards halogenated benzoic and arylacetic acids.
Collapse
|